Latest Headlines

Latest Headlines

BioFire buy boosts bioMérieux earnings

France's bioMérieux reported a rise in quarterly earnings of 3.3%, compared to the first three months of 2013, to $512.50 million.

Guardant Health snags $30M in Series B money to support blood sample cancer test

California startup Guardant Health, which sells a cancer test based on blood samples instead of biopsies, has raised $30 million in Series B financing more than two months after garnering $10 million in a round led by Sequoia Capital.

Quest buys Summit Health as it aims to restore growth

Quest Diagnostics' revenues fell in the fourth quarter of 2013--a direct violation of its 5-point strategy including "restore growth"--but the company thinks its acquisition of prevention and wellness services outfit Summit Health will help fix those problems.

Foundation Medicine ditches plans to raise $150M

The bearish market that led Lombard Medical to delay its IPO and TriVascular Technologies to price below its range has scuttled a fundraise from diagnostics luminary Foundation Medicine.

Qiagen puts up $10M to boost its diagnostics manufacturing

Molecular diagnostics company Qiagen will invest $10 million to build out manufacturing capabilities at its Germantown, MD, campus by early 2015, focusing on products for women's health and infectious disease.

Abbott wins FDA nod for diabetes blood test

Abbott Laboratories has secured the FDA's blessing to launch its latest diabetes diagnostic, a test that can help diagnose and monitor diabetics as well as flag patients at risk for developing the disease.

SQI snags $4.2M to dial up its marketing push

SQI Diagnostics has raised $4.2 million through a public offering, selling off shares and warrants to bankroll its commercialization plans.

Adaptive Biotechnologies raises $120M to bolster its immune Dx

Seattle-based Adaptive Biotechnologies announced April 7 that it has completed two rounds of financing, netting the company $120 million that it will use to expand sales of existing products and develop new ones. 

Merck KGaA signs on to sell Auxogyn's IVF test

Germany's Merck KGaA signed a licensing agreement with Menlo Park, CA-based Auxogyn to sell its fertility-enhancing diagnostic test in Europe and Canada with an option to extend the agreement to other countries.

Exact Sciences raises $120M to get its cancer test on the market

A week after swaying an FDA panel with its colorectal cancer test, Exact Sciences raised $119.7 million through a stock offering, flipping 10 million shares at $12.75 each.